Compare Citius Pharmaceuticals Inc (CTXR) vs Corning Incorporated (GLW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Corning Incorporated — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Corning Incorporated trades at $173.13 (market cap $161.49B). The key difference: Corning Incorporated is far larger — about 11030.7× Citius Pharmaceuticals Inc's market cap, and Corning Incorporated pays a 0.6% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | GLW | |
|---|---|---|
Market Cap | $14.64M | $161.49B |
Sector | Health | Technology |
52-Week High | $1.82 | $255.79 |
52-Week Low | $0.53 | $52.52 |
Enterprise Value | $10.86M | $169.66B |
Dividend Yield | — | 0.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Corning (GLW) trades at $183.36, down 3.92% amid a broader AI infrastructure stock selloff. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $0.70 versus $0.692 expected, marking the fourth consecutive earnings beat. Revenue growth accelerated to $15.63 billion in 2025 with net income margin improving to 10.21%. Technical indicators show bearish momentum with the price testing support at $181, while RSI at 46.51 suggests neutral momentum conditions.
GLW presents a compelling long-term opportunity with 54% analyst buy ratings and a $210.10 consensus price target representing 15% upside. Key risks include China exposure, consumer electronics cyclicality, and competitive pressures in optical communications. The company's AI partnerships with NVIDIA and Amazon position it well for sustained growth in fiber and connectivity markets despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →
